Project Grant K22CA289207
Award Date
9/1/24
Completion Date
8/31/27
Dollars Obligated
$194K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02142, USA
Similar Awards
This $1,480,500 federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) aims to elucidate the cell intrinsic and extrinsic mechanisms underlying small cell lung cancer (SCLC) metastasis. The project will develop cutting-edge technologies to establish a comprehensive, spatiotemporally-resolved lineage tracing platform capable of recording the entire course of SCLC metastasis. Specifically, the...
This is a Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research federal grant program (CFDA 93.395). The project aims to investigate the therapeutic targeting of SMARCA2, a chromatin remodeling subunit, in lung cancers with SMARCA4 deficiency. The $557,418 award will support the development of genetically engineered mouse models to evaluate the impact of SMARCA2 degradation on tumor progression and to elucidate the underlying mechanisms. The research...
This $631,156 federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research to uncover mechanisms driving lineage plasticity in lung cancer. The award recipient, the Icahn School of Medicine at Mount Sinai, will systematically investigate how genetic and epigenetic changes, particularly in the Notch signaling pathway and lineage-determining transcription factors, contribute to the transition from lung adenocarcinoma to the...
This federal Project Grant award, issued by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research at New York University School of Medicine to investigate the molecular mechanisms underlying the adeno-to-squamous transition in non-small cell lung cancer treatment. The $703,410 award, with a project period from January 16, 2025 to December 31, 2029, aims to identify vulnerabilities in the chromatin regulators driving this adaptive...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $953,982 to The Trustees of Columbia University in the City of New York to investigate mechanisms of tumor plasticity in human bladder cancer. The research aims to elucidate the mechanistic basis for the phenotypic switch between luminal and basal subtypes of bladder tumors, which is associated with disease progression and therapeutic response....
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $164,500 to The Trustees of Columbia University in the City of New York to investigate the mechanisms by which the protein S100A9 mediates brain metastasis in epidermal growth factor receptor (EGFR)-mutant lung cancer. The key goals are to: Examine how S100A9 expression is epigenetically regulated by histone methylation and the MEIS1 transcription factor in brain metastasis-prone cells....
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $696,569 to New York University School of Medicine to conduct research aimed at developing novel therapies for lung cancer. The key objectives are to: 1) characterize the impact of the protein lipocalin 2 (LCN2) on the tumor microenvironment, 2) develop antibody-based therapeutics that interfere with LCN2 and assess their efficacy as monotherapy and in combination with immune checkpoint...
This $230,010 project grant awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to unravel the drivers of metastasis in small cell lung cancer (SCLC) using human pluripotent stem cell-based models. The research strategy integrates stem cell-derived SCLC models, clinical samples, patient-derived xenografts, and advanced technologies like single-cell sequencing to examine cell behavior in primary tumors and metastatic sites....
This federal Project Grant award, valued at $234,730.00, was provided by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The funding supports research to define the transcriptional and epigenetic signatures in normal lung tissue that predispose to lung cancer development, as well as the molecular phenotypes of resulting lung tumors in a mouse model. The central hypothesis is that preexisting epigenetic perturbations in lung tissue...
The National Cancer Institute (NCI) awarded a $256,487 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research in New York, NY. The purpose of this 5-year grant is to develop multimodal predictive models that integrate real-world data from circulating tumor DNA (ctDNA) sequencing, radiomics, tumor registries, and tissue genomics to improve risk stratification and clinical management of non-small cell lung cancer (NSCLC). The...